trial

Effects of CDP-Choline on Gating and Cognitive Deficits in First Episode Schizophrenia

NCTId NCT02088983
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Unknown
Enrollment 40 (estimated)
Sponsored by University of Ottawa
Primary completion 2015-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Unknown
Enrollment
40 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2014-04
Primary completion
2015-04
Eligibility
ALL · 18 Years · 35 Years

Interventions & indications

Drugs
CDP-cholineCellulose

Sponsors

University of OttawaLead Sponsor
The Ottawa HospitalCollaborator

Investigators

1
Verner Knott, PhDPrincipal Investigator

Sites

1 total
Ottawa, Canada

Linked catalysts

1
Effects of CDP-Choline on Gating and Cognitive Deficits in First Episode Schizop — primary completion2015-04

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE2
Primary Completion Date
2015-04
Status
UNKNOWN
relationships
The graph out of here
drug
CDP-choline
drug
Cellulose
drug
lead_sponsor
University of Ottawa
company
collaborator
The Ottawa Hospital
company
indication
First Episode Schizophrenia
indication
investigator
Verner Knott, PhD
person